GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Searle Co Ltd (KAR:SEARL) » Definitions » Altman Z-Score

The Searle Co (KAR:SEARL) Altman Z-Score : 2.49 (As of Dec. 13, 2024)


View and export this data going back to 1993. Start your Free Trial

What is The Searle Co Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2.4 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

The Searle Co has a Altman Z-Score of 2.49, indicating it is in Grey Zones. This implies that The Searle Co is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for The Searle Co's Altman Z-Score or its related term are showing as below:

KAR:SEARL' s Altman Z-Score Range Over the Past 10 Years
Min: 1.29   Med: 4.5   Max: 16.37
Current: 2.4

During the past 13 years, The Searle Co's highest Altman Z-Score was 16.37. The lowest was 1.29. And the median was 4.50.


The Searle Co Altman Z-Score Historical Data

The historical data trend for The Searle Co's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Searle Co Altman Z-Score Chart

The Searle Co Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.13 3.06 2.28 1.37 1.83

The Searle Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 1.42 1.38 1.83 1.83

Competitive Comparison of The Searle Co's Altman Z-Score

For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Searle Co's Altman Z-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Searle Co's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where The Searle Co's Altman Z-Score falls into.



The Searle Co Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The Searle Co's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2392+1.4*0.1985+3.3*0.0706+0.6*2.1287+1.0*0.4135
=2.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was ₨63,272 Mil.
Total Current Assets was ₨40,141 Mil.
Total Current Liabilities was ₨25,007 Mil.
Retained Earnings was ₨12,560 Mil.
Pre-Tax Income was 482.763 + 1351.427 + -491.022 + 11.964 = ₨1,355 Mil.
Interest Expense was -755.226 + -436.86 + -995.088 + -922.548 = ₨-3,110 Mil.
Revenue was 7624.184 + 547.046 + 8768.341 + 9223.193 = ₨26,163 Mil.
Market Cap (Today) was ₨60,454 Mil.
Total Liabilities was ₨28,399 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(40141.025 - 25006.992)/63272.472
=0.2392

X2=Retained Earnings/Total Assets
=12559.602/63272.472
=0.1985

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(1355.132 - -3109.722)/63272.472
=0.0706

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=60453.526/28398.942
=2.1287

X5=Revenue/Total Assets
=26162.764/63272.472
=0.4135

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

The Searle Co has a Altman Z-Score of 2.49 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


The Searle Co  (KAR:SEARL) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


The Searle Co Altman Z-Score Related Terms

Thank you for viewing the detailed overview of The Searle Co's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


The Searle Co Business Description

Traded in Other Exchanges
N/A
Address
Tipu Sultan Road, Plot No. 1, One IBL Centre, 2nd Floor, Block 7 and 8, D.M.C.H.S, Off Shahra-e-Faisal, Karachi, SD, PAK, 75530
The Searle Co Ltd is a pharmaceutical company. It is principally engaged in the manufacture of pharmaceutical and other consumer products. The company manufactures pharmaceutical products like Hydryllin, Extor, Nuberol, Forte, Peditral, Selanz SR, Tramal, and other products. Its pharmaceutical product range covers the therapeutic areas of cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care.

The Searle Co Headlines

No Headlines